What is NAFLD/NASH?

Non-alcoholic fatty liver disease (NAFLD)
Is a condition where there is too much fat built up in the liver. If left untreated, it can lead to serious liver problems.
Non-alcoholic Steatohepatitis (NASH)
Is caused when that extra fat turns into inflammation (swelling in the liver) and fibrosis (scarring) of the liver. If severe enough, that can lead to cirrhosis or liver cancer, potentially requiring a liver transplant.

the epidemic levels of obesity and type 2 diabetes mellitus (DM) in the Middle East region have also led to a significant increase in NAFLD cases. It is predicted that NAFLD and its progression to nonalcoholic steatohepatitis (NASH) will be one of the driving factors in liver disease burden in the region from 2017 to 2030. Shockingly, 1 in 3 adults in the region are currently affected by NAFLD, making it a potential pandemic.

Moreover, research has shown that more than 6 out of 10 diabetics and 9 out of 10 severely obese individuals also have NAFLD. This highlights the urgent need for effective detection and management of this condition.

The current detective tools (Biopsy and imaging) are not enough for early detection and over 50% of patients are undiagnosed.
Unicus in collaboration with its principal FIBRONOSTICS provides an innovative and new detection tool through artificial intelligence, neural network-based machine learning correlate blood biomarker combinations for screening and monitoring NAFLD patients.
More information on NAFLD/NASH
Click On The Logo To Visit Website!